Ask AI
ProCE Banner Activity

Navigating ESR1 Mutations in Metastatic HR+ HER2− Breast Cancer: Testing, Treatment, and Outcomes

Video

This presentation offers a comprehensive review of ESR1 mutations in hormone receptor-positive (HR+) HER2-negative metastatic breast cancer, focusing on their role in breast cancer biology, patient outcomes, treatment decision-making, and clinical practice. The session will discuss the role of ESR1 mutations, current guidelines for ESR1 mutation testing and treatment, and the evolving treatment landscape. It will also highlight findings from major clinical trials involving patients with relapsed HR+ HER2-negative metastatic breast cancer, both with and without ESR1 mutations.

Released: December 16, 2025